SUPN FY 2021 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

FY 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$580M+11.4% YoY

Gross Profit

$505M87.1% margin

Operating Income

$86M14.8% margin

Net Income

$53M9.2% margin

EPS (Diluted)

$0.98

Cash Flow

Operating Cash Flow

$127M

Free Cash Flow

$125M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$1.7B

Total Liabilities

$873M

Stockholders' Equity

$816M

Cash & Equivalents

$203M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$580M	$520M	+11.4%
Gross Profit	$505M	$468M	+7.9%
Operating Income	$86M	$174M	-50.5%
Net Income	$53M	$127M	-57.9%